VivoSeq
Infectious Disease

Mycobacterium Avium Complex Pulmonary Disease

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Mycobacterium Avium Complex Pulmonary Disease is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Completed1 · 33%

Clinical Trials

Trial Activity

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
Recruiting·—·Phase 4·NCT07213765·188 enrolled
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
Completed·NNational Jewish Health·Phase 2·NCT00004689·50 enrolled
Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease
Recruiting·—·Phase 4·NCT07174076·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)